Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir plus tenofovir alafenamide dual therapy versus continued standard triple ART in virologically suppressed adults with HIV
IRCT20191005044984N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of dolutegravir and tenofovir alafenamide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: HIV viral load, CD4 cell count and 2 more. Started Nov 2019; status: completed.
02
Drugs
dolutegravirtenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on IRCT20191005044984N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191005044984N1.